OpGen reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe’s In Depth Symposium session ‘The Year in Clinical Microbiology’ on June 17th in Houston, TX. Based on over 1,800 patient samples, the presentation titled “Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens” summarized the objectives of the clinical trial, the Unyvero UTI panel coverage and result evaluation recommendations based on multiple reference testing methods applied during the study. In another poster presentation titled “Multiplex Molecular Panel as a Supplement to Routine Culture for Tissue Infection,” the authors Cox et al. at the University of Cincinnati concluded that “multiplex PCR panel may play an important role in supplementing routine laboratory testing and improving the diagnostic yield for tissue infections for culture-negative results.” This was based on a study of 47 tissue homogenate samples tested with Unyvero Implant and Tissue Infection cartridges in a research use only setting. In that study, Unyvero ITI performed at a sensitivity of 81.5% compared to culture which showed a sensitivity of 72.2%.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OPGN:
- OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
- OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
- OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
- OpGen Announces Closing of $3.5 Million Public Offering
- OpGen Announces Pricing of $3.5 Million Public Offering